Dexcom chair sells 26,756 shares under 10b5-1 plan
Dexcom Inc. Executive Chair Kevin R. Sayer sold 26,756 shares of common stock in an open-market transaction at $72.00 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Dexcom Inc. Executive Chair Kevin R. Sayer sold 26,756 shares of common stock in an open-market transaction at $72.00 per share. The sale was executed under a Rule 10b5-1 trading plan that Sayer adopted on February 18, 2026 to allow orderly dispositions of his holdings.
After the transaction, Sayer directly owns 355,726 Dexcom shares, which include 106,972 unvested restricted stock units scheduled to vest in tranches through March 8, 2028. The filing shows he retains a substantial equity position following this planned sale.
Insider Trade Summary 10b5-1
Net Seller: 26,756 shares
Net Sell
1 txn
Insider
SAYER KEVIN R
Role
Executive Chair
Sold
26,756 shs ($1.93M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 26,756 | $72.00 | $1.93M |
Holdings After Transaction:
Common Stock — 355,726 shares (Direct)
Footnotes (2)
- F1. On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan.
- F2. Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027.
Key Figures
Shares sold: 26,756 shares
Sale price: $72.00 per share
Shares held after: 355,726 shares
+5 more
8 metrics
Shares sold
26,756 shares
Open-market sale on July 6, 2026
Sale price
$72.00 per share
Price for common stock sold
Shares held after
355,726 shares
Direct ownership following the transaction
Unvested RSUs
106,972 units
Included within post-transaction holdings
2026 RSU grant
32,749 units
Granted March 8, 2026, vesting through March 8, 2027
2025 RSU grant
56,993 units
Granted March 8, 2025, vesting through March 8, 2028
2024 RSU grant
17,230 units
Granted March 8, 2024, vesting through March 8, 2027
10b5-1 plan adoption
February 18, 2026
Date Sayer adopted Rule 10b5-1 trading plan
Key Terms
Rule 10b5-1 Plan, open-market sale, restricted stock units, unvested, +1 more
5 terms
Rule 10b5-1 Plan regulatory
"This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer."
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
open-market sale financial
"transaction_action: "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
restricted stock units financial
"Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted..."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
unvested financial
"Included in this number are 106,972 unvested restricted stock units..."
Executive Chair other
"officer_title: "Executive Chair""
An executive chair is the board chairperson who also takes an active, hands-on role in company management, typically working closely with the CEO and senior team to shape strategy and major decisions. For investors it matters because this blend of oversight and operational power can accelerate strategic moves and provide steady leadership—like a coach who also calls plays—but it can also concentrate authority and create governance or succession risks if too much depends on one person.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Dexcom (DXCM) report for Kevin R. Sayer?
Dexcom reported that Executive Chair Kevin R. Sayer sold 26,756 shares of common stock at $72.00 per share. The transaction was an open-market sale under a pre-arranged Rule 10b5-1 trading plan adopted on February 18, 2026.
What unvested equity awards does Kevin R. Sayer have in Dexcom (DXCM)?
Sayer’s post-transaction holdings include 106,972 unvested restricted stock units. These consist of 32,749 units granted March 8, 2026, 56,993 units granted March 8, 2025, and 17,230 units granted March 8, 2024, vesting through March 8, 2028.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates